/l, 64% segmented cells, 12% bands, 7% metamyelocytes, 7% myelocytes, 2% eosinophils, 2% monocytes and 6% lymphocytes. She had no liver or spleen enlargement. Cytogenetic bone marrow examination confirmed the presence of the Philadelphia chromosome with karyotype 46, XX, t(9,22) (q34, q11) in all mitoses and polyploidy in 28% of mitoses. The patient agreed to an abortion and interferon treatment in escalating doses was subsequently started. After 3 months, hematological remission was achieved but without any cytogenetic response after 1 year of treatment. In spite of the interferon treatment, which continued until January 1997, the leukocyte count increased to 98 × 10 9 /l, and platelets to 1160 × 10 9 /l. The white blood cell differential showed 32% of promyelocytes and blasts in the peripheral blood and 8% blasts in the bone marrow. There was still no liver or spleen enlargement. Interferon was discontinued and hydroxyurea treatment was started. Examination of peripheral blood by reverse-transcriptase polymerase chain reaction (RT-PCR) showed the micro bcr BCR/ABL gene with an e19a2 junction ( Figure 1 ). Since there was no HLA compatible donor in her core and extended family, an international search was started. However, no unrelated donor compatible for HLA-A, -B, DR and DQ antigens was found because of the unusual HLA phenotype of the patient. An unrelated bone marrow transplant with one allele DR mismatched donor was performed in June 1997. On day 28 post transplant, the absolute nucleated cell (ANC) count was unfortunately still less than 0.5 × 10 9 /l. Despite two HLA mismatches it was decided to infuse bone marrow from her mother without further conditioning. Since no sufficient engraftment was achieved, the patient was conditioned in September 1997 with fludarabine monophosphate 30 mg/m 2 /day for 5 consecutive days and G-CSF-stimulated peripheral progenitor cells of her mother were given 40 days after this retransplantation. The patient was discharged with a normal blood count and in good condition. At present she is 20 months after the last transplantation in complete hematological and molecular remission of her disease.
The RT-PCR of RNA from peripheral blood leukocytes with BCR e13 and ABL a3 primers, 10 and the second nested PCR with BCR e19 and ABL a2 primers, 2 performed according to a procedure described elsewhere, 7 showed, before the first transplantation, a band of the same size as the previously reported e19a2 micro bcr patient 7 ( Figure 1a  and b) .
The patient referred to here is important for two reasons. She is another case of 'classic' CML with micro bcr BCR/ABL gene documenting that patients with this variant of BCR/ABL gene are not only those with a mild course of the disease. The referred patient, with other patients published so far, [2] [3] [4] [5] [6] [7] [8] [9] show that the micro bcr CML patients having the e19a2 junction can be in mild, average and high risk stages of the disease. Consequently, the decision about correct treatment of these patients is not easy at present. We do not know of any prognostic factors separating e19a2 CML patients into mild, average and high risk groups, but we must remember that some of these patients can go through an acceleration and transformation. In our opinion, the only possibility at present is to monitor the development of disease in these patients very carefully. As soon as the first signs of previous treatment refractoriness and acceleration are noticed, allogeneic transplantation should be indicated in cases with an accessible marrow donor. A severe course of the disease in our patient was documented by refractoriness to the chemotherapy treatment and by a development of an accelerated phase. To our knowledge, our patient is the first case of a micro bcr CML patient to be treated by bone marrow transplantation. 
Factor V Leiden mutation as a predisposing factor for veno-occlusive disease following BMT
In a recent issue of this journal, Duggan et al 1 retrospectively evaluated the importance of factor V Leiden (1691 G-A) and the prothrombin gene 20210 G-A mutations as a predisposing factor for veno-occlusive disease (VOD) following BMT. In their study, 15 of the 22 patients who developed VOD and 51 patients without VOD following BMT were evaluated. The authors concluded that the prothrombin gene 20210 G-A but not factor V Leiden mutation may increase the risk of VOD in BMT patients but also that prospective confirmation with larger studies is needed. We would like to share our experience which is in contrast with the conclusion of this study.
In December 1997, we initiated a prospective study in children, looking at the association of inherited abnormalities known to predispose to thrombosis and VOD following BMT. VOD was diagnosed on the basis of clinical criteria, as previously described, 2 similar to Duggan et al's study. Severity of VOD was scored as mild, moderate or severe as previously defined. 2 The laboratory evaluation of inherited hypercoagulable abnormalities included functional anticoagulant assays for protein C, protein S, antithrombin III (ATIII), factor VIII and genetic analysis of the factor V Leiden and prothrombin 20210 G-A mutation before conditioning therapy. Genetic analyses were performed as previously described. 3, 4 In this ongoing prospective study, 10 consecutive children who received allogeneic BMT were included. The underlying diseases were as follows: AML (n = 5), juvenile myelomonocytic leukemia (n = 1), ␤-thalassemia major (n = 2), SAA (n = 1), Fanconi's anemia (FA; n = 1). Conditioning therapy was with BU 640 mg/m 2 and CY 200 mg/kg for leukemia, BU 480 mg/m 2 and CY 200 mg/kg for thalassemia, ATG (horse, Pasteur-Merieux, Lyon, France) 30 mg/kg and CY 200 mg/kg for SAA, BU 6 mg/kg and CY 40 mg/kg for FA.
There were four cases of VOD: one patient with thalassemia had mild and three patients (two AML, one thalassemia) had moderate VOD. Laboratory evaluation of inherited hypercoagulable abnormalities indicated that three of the four had factor V Leiden heterozygosity. None of these patients had prothrombin gene 20210 G-A mutation. Protein C, protein S, ATIII, and factor VIII levels were in the normal range. Our previous population study 3 had revealed that factor V Leiden heterozygosity was 9.8% with an allelic frequency of 4.9 which is one of the highest in the Western population. Prothrombin gene 20210 G-A heterozygosity was also found to be 2.7% in the Turkish population.
